| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Martijn Meeter, Lucia Talamini, Jeroen A J Schmitt, Wim J Riede. Effects of 5-HT on memory and the hippocampus: model and data. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 4. 2006-05-25. PMID:16132065. |
the results suggest that the memory impairments in depressed subjects may be related to 5-ht undertransmission, and support the notion that 5-ht1a agonists ameliorate memory deficits in depression. |
2006-05-25 |
2023-08-12 |
human |
| Malika Robichaud, Guy Debonne. Allopregnanolone and ganaxolone increase the firing activity of dorsal raphe nucleus serotonergic neurons in female rats. The international journal of neuropsychopharmacology. vol 9. issue 2. 2006-05-25. PMID:16174428. |
both 5-ht and neurosteroids seem to play an important role in the pathophysiology of major depression. |
2006-05-25 |
2023-08-12 |
rat |
| Jeffrey R Lacasse, Jonathan Le. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS medicine. vol 2. issue 12. 2006-05-18. PMID:16268734. |
serotonin and depression: a disconnect between the advertisements and the scientific literature. |
2006-05-18 |
2023-08-12 |
Not clear |
| Jeffrey L Rausch, Maria E Johnson, Junqing Li, Julian Hutcheson, Benjamin M Carr, Katina M Corley, Amanda B Gowans, Joseph Smit. Serotonin transport kinetics correlated between human platelets and brain synaptosomes. Psychopharmacology. vol 180. issue 3. 2006-05-16. PMID:15726335. |
blood platelets have been used extensively as a model system for investigating the role of the serotonin transporter (sert) in various psychiatric disorders, especially depression. |
2006-05-16 |
2023-08-12 |
human |
| Craig J Whittington, Tim Kendall, Steve Pillin. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Current opinion in psychiatry. vol 18. issue 1. 2006-05-16. PMID:16639179. |
this article summarizes recent developments in the use of selective serotonin reuptake inhibitors and atypical antidepressants to treat children and adolescents with depression at a time when their use in this context has generated considerable controversy and confusion for clinicians, patients and their families. |
2006-05-16 |
2023-08-12 |
Not clear |
| Marcus R Munafò, Taane G Clark, Kate H Roberts, Elaine C Johnston. Neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. Neuropsychobiology. vol 53. issue 1. 2006-05-11. PMID:16319503. |
neuroticism mediates the association of the serotonin transporter gene with lifetime major depression. |
2006-05-11 |
2023-08-12 |
Not clear |
| Carol A Shively, David P Friedman, H Donald Gage, Michael C Bounds, Clive Brown-Proctor, Joseph B Blair, Jessica A Henderson, Michael A Smith, Nancy Buchheime. Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys. Archives of general psychiatry. vol 63. issue 4. 2006-05-11. PMID:16585468. |
behavioral depression and positron emission tomography-determined serotonin 1a receptor binding potential in cynomolgus monkeys. |
2006-05-11 |
2023-08-12 |
monkey |
| Fatemeh Moghaddas, Jonas Lidfeldt, Christina Nerbrand, Helena Jernström, Göran Samsio. Prevalence of urinary incontinence in relation to self-reported depression, intake of serotonergic antidepressants, and hormone therapy in middle-aged women: a report from the Women's Health in the Lund Area study. Menopause (New York, N.Y.). vol 12. issue 3. 2006-05-09. PMID:15879921. |
to study a perceived relationship of urinary incontinence with self-reported depression among middle-aged women, and to outline whether hormone therapy, selective serotonin reuptake inhibitors, or serotonin norepinephrine reuptake inhibitors influence the prevalence of urinary incontinence. |
2006-05-09 |
2023-08-12 |
Not clear |
| Shigeyuki Chaki, Yuichi Oshida, Shin-Ichi Ogawa, Takeo Funakoshi, Toshiharu Shimazaki, Taketoshi Okubo, Atsuro Nakazato, Shigeru Okuyam. MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity. Pharmacology, biochemistry, and behavior. vol 82. issue 4. 2006-05-09. PMID:16337261. |
moreover, blockade of both the mc4 receptor and serotonin reuptake sites might represent a useful approach in the treatment of anxiety and depression. |
2006-05-09 |
2023-08-12 |
rat |
| C Schüle, E Romeo, D P Uzunov, D Eser, F di Michele, T C Baghai, A Pasini, M Schwarz, H Kempter, R Rupprech. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Molecular psychiatry. vol 11. issue 3. 2006-05-02. PMID:16344854. |
concentrations of 3alpha-reduced neuroactive steroids are altered in depression and normalize after antidepressant pharmacotherapy with selective serotonin re-uptake inhibitors (ssris). |
2006-05-02 |
2023-08-12 |
Not clear |
| Paul E Holtzheimer, Charles B Nemerof. Advances in the treatment of depression. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics. vol 3. issue 1. 2006-05-02. PMID:16490412. |
currently available treatments for depression include tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, various atypical antidepressants, and electroconvulsive therapy. |
2006-05-02 |
2023-08-12 |
Not clear |
| Pinhas N Dannon, Katherine Lowengrub, I Iancu, Moshe Kotle. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert review of neurotherapeutics. vol 4. issue 2. 2006-04-25. PMID:15853560. |
paroxetine is unique among the selective serotonin reuptake inhibitors since, in addition to its effect on the cns serotonergic neurotransmission, it also has mild noradrenergic properties demonstrated to be effective in the treatment of anxiety disorders and depression. |
2006-04-25 |
2023-08-12 |
Not clear |
| David R P Gua. A renaissance for fluoxetine in the management of depression in the elderly? The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. vol 18. issue 1. 2006-04-25. PMID:16563053. |
to review the literature pertaining to the use of the selective serotonin reuptake inhibitor (ssri) fluoxetine in the management of depression in elders. |
2006-04-25 |
2023-08-12 |
Not clear |
| Michael T Eaddy, Benjamin G Druss, Matthew W Sarnes, Timothy S Regan, Laura E Franku. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database. Journal of managed care pharmacy : JMCP. vol 11. issue 2. 2006-04-20. PMID:15766321. |
administrative claims data analysis performed in the early 1990s found lower total medical costs for patients with depression who remained on antidepressant therapy with selective serotonin reuptake inhibitors (ssris) for at least 90 days compared with patients who discontinued therapy prior to 60 days. |
2006-04-20 |
2023-08-12 |
Not clear |
| A A Tahami Monfared, D Han, O Sheehy, B Bexton, J Lelorie. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study. Current medical research and opinion. vol 22. issue 1. 2006-04-20. PMID:16393434. |
empirical studies of antidepressant cost-effectiveness suggest that the use of venlafaxine may be no more costly than selective serotonin reuptake inhibitors (ssris) in the treatment of depression. |
2006-04-20 |
2023-08-12 |
Not clear |
| K Deshpand. Isolated fluvoxamine poisoning presenting with hypertonia and seizures: a case report. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. vol 4. issue 3. 2006-04-20. PMID:16573427. |
the recent introduction of selective serotonin reuptake inhibitors (ssris) has represented a major advance in the management of depression. |
2006-04-20 |
2023-08-12 |
Not clear |
| Paulajo Malin, Steven P Wengel, William J Burk. Escitalopram: better treatment for depression is through the looking glass. Expert review of neurotherapeutics. vol 4. issue 5. 2006-04-18. PMID:15853504. |
with the introduction of the selective serotonin reuptake inhibitors in the 1980s, patients were afforded treatment for depression that was both safer and better tolerated than any prior treatment modality offered. |
2006-04-18 |
2023-08-12 |
Not clear |
| W N Shaw, J A Clemens, J A Panett. LY226936 administered orally and centrally to obese Zucker rats suppresses food intake and body weight gain. Obesity research. vol 2. issue 5. 2006-04-17. PMID:16353597. |
none of the receptors studied (mu and kappa opioid, cck, serotonin, neuropeptide y, galinin, n-methyl-d-aspartic acid) appeared to bind ly226936 and therefore, appear not to be involved in the depression of food intake by the obese zucker rat. |
2006-04-17 |
2023-08-12 |
rat |
| Iu V Karakulova, A A Shuto. [Quantitative determination of serum serotonin in the diagnosis of tension headache]. Klinicheskaia laboratornaia diagnostika. issue 1. 2006-04-12. PMID:16512474. |
a course of antidepressant therapy with prodep ameliorated headache and depression in the presence of higher serum serotonin levels. |
2006-04-12 |
2023-08-12 |
Not clear |
| Iu V Karakulova, A A Shuto. [Quantitative determination of serum serotonin in the diagnosis of tension headache]. Klinicheskaia laboratornaia diagnostika. issue 1. 2006-04-12. PMID:16512474. |
serum serotonin may be regarded as a marker of the severity of pain and depression in patients with chronic tension headache and be an objective indicator of the efficiency of antidepressant therapy. |
2006-04-12 |
2023-08-12 |
Not clear |